作者
Henry Krum, Markus P Schlaich, Paul A Sobotka, Michael Böhm, Felix Mahfoud, Krishna Rocha-Singh, Richard Katholi, Murray D Esler
发表日期
2014/2/15
期刊
The Lancet
卷号
383
期号
9917
页码范围
622-629
出版商
Elsevier
简介
Background
Renal denervation (RDN) with radiofrequency ablation substantially reduces blood pressure in patients with treatment-resistant hypertension. We assessed the long-term antihypertensive effects and safety.
Methods
Symplicity HTN-1 is an open-label study that enrolled 153 patients, of whom 111 consented to follow-up for 36 months. Eligible patients had a systolic blood pressure of at least 160 mm Hg and were taking at least three antihypertensive drugs, including a diuretic, at the optimum doses. Changes in office systolic blood pressure and safety were assessed every 6 months and reported every 12 months. This study is registered with ClinicalTrials.gov, numbers NCT00483808, NCT00664638, and NCT00753285.
Findings
88 patients had complete data at 36 months. At baseline the mean age was 57 (SD 11) years, 37 (42%) patients were women, 25 (28%) had type 2 diabetes mellitus, the mean …
引用总数
20132014201520162017201820192020202120222023202431481431087957634156303421